Live Well Be Well with Sarah Ann Macklin | Health, Lifestyle, Nutrition

This One Gut Microbe Could Decide If Cancer Treatment Works | William Li

Feb 6, 2026
William Li, physician-scientist known for gut microbiome and metabolism research, talks about Akkermansia muciniphila and its surprising roles. He covers how this keystone microbe links to insulin sensitivity, GLP-1 release, vascular and brain effects. He also explores associations between Akkermansia and cancer immunotherapy response, plus clinical implications for patient care.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Keystone Bacterium For Metabolism

  • Akkermansia muciniphila is a recently discovered keystone gut bacterium that improves insulin sensitivity and glucose regulation.
  • William Li highlights clinical studies showing it can lower hemoglobin A1c and sharpen metabolic control.
INSIGHT

Microbe Links To GLP-1 And Circulation

  • Akkermansia can stimulate the body's release of GLP-1, a hormone affecting metabolism and blood vessels.
  • GLP-1 receptors exist on blood vessels throughout the body, including the brain, linking gut microbes to circulation and brain health.
INSIGHT

Gut Microbe Predicts Immunotherapy Response

  • Research found a strong association between Akkermansia presence and positive responses to cancer immunotherapy.
  • Laurence Vogel's study showed responders had Akkermansia while non-responders lacked it, suggesting gut microbes affect immunotherapy success.
Get the Snipd Podcast app to discover more snips from this episode
Get the app